Analyst Price Target is $16.00
▲ +174.44% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Inozyme Pharma in the last 3 months. The average price target is $16.00, with a high forecast of $23.00 and a low forecast of $14.00. The average price target represents a 174.44% upside from the last price of $5.83.
Current Consensus is
Buy
The current consensus among 5 contributing investment analysts is to buy stock in Inozyme Pharma. This Buy consensus rating has held steady for over two years.
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Read More